Tuesday, Jul 5, 1988
South San Francisco, Calif. -- July 5, 1988 --Axel Ullrich, staff scientist at Genentech and the first researcher to clone the insulin gene, has been appointed director at the Max Planck Institute of Biochemistry in Munich, Germany. In his new role, Ullrich will concentrate on studies into the molecular basis of growth control and related pathological disorders, including cancer.
The Max Planck Society is the major government-funded organization for basic scientific research in West Germany. Ullrich will continue to collaborate and consult exclusively with Genentech in the general field of cancer research and therapy.
"Genentech is proud of Axel Ullrich's appointment as director at the Max Planck Institute of Biochemistry," said Robert A. Swanson, chief executive officer. "We are delighted that he can fulfill his long-term plan to return to academia while continuing a productive relationship with the company. The flow of science and scientists to and from academic institutions is one of the key strengths of Genentech's research organization."
Ullrich joined Genentech in 1979, having earlier determined the molecular structure of the insulin gene in experiments at the University of California-San Francisco. He was the first person to clone a substance of relevance to a major human disease using recombinant DNA technology.
Holder of a doctorate in biochemistry and molecular genetics, Ullrich has been recognized by national and international awards for his work carried out at Genentech in the areas of cancer and diabetes. These include the Paul Langerhans Medal from the German Diabetes Society.
# # #